ARCHIVES

Blue Cross, Broder Skirmish On Coverage Of Group C Drugs

This article is from The Cancer Letter archive.

Vol. 15 No. 42 | November 3, 1989

Download PDF Visit The Full Archive

Related Articles

ACS Stirs Discord By Placing Its Own Logo On A Coalition’s Petition, Then Reconsiders

February 7, 1997

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

December 2, 1983

Report Tells NCI to Increase Funding for SPOREs.

June 30, 2006

NCCN Guidelines Retain Avastin For Breast Cancer

October 22, 2010

Radioactive Seeds Tested In Treatment Of NSCLC

September 26, 2008

Cancer Panel Report Urges Removal Of Barriers To Care.

December 7, 2001